UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease

Alimentary pharmacology & therapeutics, 2018-08, Vol.48 (3), p.347-357

2018

Volltextzugriff (PDF)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (1), p.65-77

2018

Volltextzugriff (PDF)

Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials

Alimentary pharmacology & therapeutics, 2015-11, Vol.42 (10), p.1200-1210

2015

Volltextzugriff (PDF)

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

Alimentary pharmacology & therapeutics, 2015-01, Vol.41 (1), p.77-86

2015

Volltextzugriff (PDF)

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

Alimentary pharmacology & therapeutics, 2014-05, Vol.39 (10), p.1126-1135

2014

Volltextzugriff (PDF)

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2013-09, Vol.38 (5), p.447-459

2013

Volltextzugriff (PDF)

CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

Gut, 2004-10, Vol.53 (10), p.1485-1493

2004

Volltextzugriff (PDF)

Medical management of mild to moderate Crohn’s disease: evidence‐based treatment algorithms for induction and maintenance of remission

Alimentary pharmacology & therapeutics, 2007-10, Vol.26 (7), p.987-1003

2007

Volltextzugriff (PDF)

Systematic review with meta‐analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease

Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (2), p.114-126

2018

Volltextzugriff (PDF)

Editorial: combination immunosuppressive therapy to treat Crohn’s disease – ready for all age groups? Authors' reply

Alimentary pharmacology & therapeutics, 2019-06, Vol.49 (12), p.1529-1529

2019

Volltextzugriff (PDF)

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

Clinical pharmacology and therapeutics, 2012-04, Vol.91 (4), p.635-646

2012

Volltextzugriff (PDF)

Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate‐to‐severe Crohn’s disease in the PRECiSE 2 study

Alimentary pharmacology & therapeutics, 2010-06, Vol.31 (12), p.1276-1285

2010

Volltextzugriff (PDF)

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Gut, 2006-11, Vol.55 (11), p.1568-1574

2006

Volltextzugriff (PDF)

Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort

Gastroenterology (New York, N.Y. 1943), 1999-07, Vol.117 (1), p.49-57

1999

Volltextzugriff (PDF)

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

Alimentary pharmacology & therapeutics, 2011-03, Vol.33 (5), p.541-550

2011

Volltextzugriff (PDF)

Evaluation of a daily practice composite score for the assessment of Crohn’s disease: the treatment impact of certolizumab pegol

Alimentary pharmacology & therapeutics, 2011-05, Vol.33 (10), p.1143-1151

2011

Volltextzugriff (PDF)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

Alimentary pharmacology & therapeutics, 2015-07, Vol.42 (2), p.188-202

2015

Volltextzugriff (PDF)

Methotrexate for induction of remission in refractory Crohn's disease

Cochrane database of systematic reviews, 2005-01 (1), p.CD003459

2005

Volltextzugriff (PDF)

A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease

The New England journal of medicine, 2000-06, Vol.342 (22), p.1627-1632

2000

Volltextzugriff (PDF)

Editorial: the impact of the placebo effect in Crohn's disease – author's reply

Alimentary pharmacology & therapeutics, 2017-06, Vol.45 (11), p.1472-1472

2017

Volltextzugriff (PDF)

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

Alimentary pharmacology & therapeutics, 2017-03, Vol.45 (5), p.617-630

2017

Volltextzugriff (PDF)

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease

Alimentary pharmacology & therapeutics, 2018-01, Vol.47 (2), p.229-237

2018

Volltextzugriff (PDF)

CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, for steroid‐dependent Crohn's disease: a randomized, double‐blind, placebo‐controlled trial

Alimentary pharmacology & therapeutics, 2006-03, Vol.23 (5), p.617-628

2006

Volltextzugriff (PDF)

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2005-12, Vol.353 (23), p.2462-2476

2005

Volltextzugriff (PDF)

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial

Alimentary pharmacology & therapeutics, 2017-01, Vol.45 (2), p.264-275

2017

Volltextzugriff (PDF)

1 – 25 von 425

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(418)
Mit Volltextzugriff
(360)

Publikationsform

Sprache

Englisch
(424)
Japanisch
(39)
Deutsch
(1)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(185)
Science & Technology
(185)
Humans
(171)
Gastroenterology & Hepatology
(136)
Female
(89)
Male
(89)
Adult
(85)
Crohn Disease - Drug Therapy
(84)
Treatment Outcome
(71)
Middle Aged
(70)
Biological And Medical Sciences
(56)
Medical Sciences
(56)
Double-Blind Method
(51)
Inflammatory Bowel Disease
(47)
Severity Of Illness Index
(46)
Crohn's Disease
(45)
Antibodies, Monoclonal - Therapeutic Use
(42)
Pharmacology & Pharmacy
(41)
Aged
(39)
Clinical Trials
(37)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials

A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity

A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease

Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial

Medical management of mild to moderate Crohn’s disease: evidence‐based treatment algorithms for induction and maintenance of remission

Systematic review with meta‐analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease

Editorial: combination immunosuppressive therapy to treat Crohn’s disease – ready for all age groups? Authors' reply

Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate‐to‐severe Crohn’s disease in the PRECiSE 2 study

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

Evaluation of a daily practice composite score for the assessment of Crohn’s disease: the treatment impact of certolizumab pegol

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

Methotrexate for induction of remission in refractory Crohn's disease

A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease

Editorial: the impact of the placebo effect in Crohn's disease – author's reply

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease

CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, for steroid‐dependent Crohn's disease: a randomized, double‐blind, placebo‐controlled trial

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial

Suchergebnisse filtern